They are most commonly prescribed in combination with lifestyle modification and metformin, sulfonylureas, thiazolidinediones, and/or basal insulin, but selected patients intolerant to or with contraindications for metformin (such as patients with chronic kidney disease) can be successfully treated with DPP-4 inhibitor monotherapy. This evidence concerns the gene DPP4 and chronic kidney disease.